948
Views
10
CrossRef citations to date
0
Altmetric
Review

Developments in predictive biomarkers for hepatocellular carcinoma therapy

, , &
Pages 63-74 | Received 27 Oct 2019, Accepted 02 Jan 2020, Published online: 07 Jan 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Zheng Guo, Nanying Zhong, Xueming Xu, Yu Zhang, Xiaoning Luo, Huabin Zhu, Xiufang Zhang, Di Wu, Yingwei Qiu & Fuping Tu. (2021) Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features. Journal of Hepatocellular Carcinoma 8, pages 773-782.
Read now

Articles from other publishers (9)

Jingtao Chen, Chao Niu, Ning Yang, Chunyan Liu, Shan-shan Zou & Shan Zhu. (2023) Biomarker discovery and application—An opportunity to resolve the challenge of liver cancer diagnosis and treatment. Pharmacological Research 189, pages 106674.
Crossref
Zhichao Feng, Huiling LiQianyun LiuJunhong DuanWenming ZhouXiaoping Yu, Qian ChenZhenguo Liu, Wei WangPengfei Rong. (2022) CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma. Radiology.
Crossref
Yujian Liu, Jingrui Yang, Rui-Sheng Ke, Lupeng Wu, Zaifa Hong, Ping Guo, Liuxing Feng & Zhimin Li. (2022) LINC02875 Upregulation Contributed to Poor Prognosis for the Hepatocellular Carcinoma and Progression for the Cancerous Cells. Hormone and Metabolic Research 54:11, pages 760-767.
Crossref
Min Yao, Jun-Ling Yang, De-Feng Wang, Li Wang, Ying Chen & Deng-Fu Yao. (2022) Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World Journal of Clinical Cases 10:11, pages 3321-3333.
Crossref
Zhipeng Zhu, Mengyu Song, Wenhao Li, Mengying Li, Sihan Chen & Bo Chen. (2021) Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Maria Tampaki, George Vasileios Papatheodoridis & Evangelos Cholongitas. (2021) Intrahepatic recurrence of hepatocellular carcinoma after resection: an update. Clinical Journal of Gastroenterology 14:3, pages 699-713.
Crossref
Yeonghak Bang, Changhoon Yoo, Sara Lonardi, Hyung-Don Kim, Caterina Vivaldi, Margherita Rimini, Giovanni Luca Frassineti, Sook Ryun Park, Mario Domenico Rizzato, Min-Hee Ryu, Francesca Salani, Ilario Giovanni Rapposelli, Baek-Yeol Ryoo, Vittorina Zagonel, Valentina Massa, Martina Valgiusti, Valentina Burgio, Mario Scartozzi, Stefano Cascinu & Andrea Casadei-Gardini. (2021) Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis. Targeted Oncology 16:3, pages 401-410.
Crossref
Constantin Dreher, Philipp Linde, Judit Boda-Heggemann & Bettina Baessler. (2020) Radiomics for liver tumours. Strahlentherapie und Onkologie 196:10, pages 888-899.
Crossref
Zhichao Feng, Huafei Zhao, Yi Jiang, Huiling Li, Zhimin Yan, Wendi Kang, Qianyun Liu, Junhong Duan, Mengtian Ma, Qin Liu, Fulong Song, Shumin Zeng, Fang Shao, Weiyan Huang, Qi Liang, Wenming Zhou, Xiaoping Yu, Qian Chen, Zhenguo Liu, Wei Wang & Pengfei Rong. (2021) Identification of Macrotrabecular-Massive Hepatocellular Carcinoma and Prediction of Response to Transarterial Chemoembolization Plus Antiangiogenic Therapy Using Ct Radiomics. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.